Physician profile
William R Dailey
NPI 1558466458
$1,367.11
in general payments reported to CMS, 2019-2025
23 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $91.19 · 2021: $34.57 · 2022: $184 · 2023: $130 · 2024: $316 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $867.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $250.07 | 2022-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $169.99 | 2020-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Astrazeneca Pharmaceuticals LP | $137.05 | 2019-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $131.93 | 2021-2024 | Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $95.31 | 2025 | Caplyta |
| Novo Nordisk INC | $77.87 | 2019-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $72.75 | 2019-2025 | |
| Glaxosmithkline, LLC. | $62.36 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $42.35 | 2019-2024 | |
| Vanda Pharmaceuticals INC. | $38.04 | 2025 | Fanapt |
| Exact Sciences Corporation | $36.58 | 2025 | Cologuard Collection Kit |
| Abbott Laboratories | $31.42 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.95 | 2019-2022 | |
| Astellas Pharma US INC | $30.37 | 2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $29.69 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $23.54 | 2019-2020 | |
| Kyowa Kirin, INC. | $19.81 | 2024 | Crysvita |
| Nevro Corp. | $17.92 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.48 | 2024 | Austedo Xr |
| Phathom Pharmaceuticals, INC. | $15.02 | 2024 | Voquezna |
| Amgen INC. | $14.17 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.62 | 2019 | |
| Sunovion Pharmaceuticals INC. | $11.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Dailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.